Toggle light / dark theme

A team led by scientists at the National Institutes of Health (NIH) has reported a research trifecta. They discovered a new vulnerable site on HIV for a vaccine to target, a broadly neutralizing antibody that binds to that target site, and how the antibody stops the virus from infecting a cell. The study was led by scientists at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases, part of NIH.

The new target is a part of HIV called the fusion peptide, a string of eight amino acids that helps the virus fuse with a cell to infect it. The fusion peptide has a much simpler structure than other sites on the virus that HIV vaccine scientists have studied.

The scientists first examined the blood of an HIV-infected person to explore its ability to stop the virus from infecting cells. The blood was good at neutralizing HIV but did not target any of the vulnerable spots on the virus where broadly neutralizing HIV antibodies (bnAbs) were known to bind.

Read more

Fox 29 — Good Day Philadelphia

http://www.fox29.com/140735577-video

Reanimalogo

NBC TV 10

http://www.nbcphiladelphia.com/news/local/Zombies-from-Phill…65101.html

fmri5

CNN en Espanol

http://cnnespanol.cnn.com/video/cnnee-encuentro-intvw-joel-o…-cerebral/

Researcher-test

Check out LEAF President Keith Comito explain the origin of Lifespan.io and why crowdfunding research to extend healthy lifespan is both important and exciting.

Our current campaign is here: https://www.lifespan.io/campaigns/the-major-mouse-testing-program/ and there will be more to follow soon! Connect with us on social media and subcribe on YouTube to stay informed. #CrowdfundTheCure #LifespanIO


LEAF President Keith Comito explains the origin of Lifespan.io — a crowdfunding platform specifically for biomedical research aimed at extending healthy human lifespan. Learn more, and help us Crowdfund the Cure for Aging: https://www.lifespan.io

Monday May 16th 17:00 GMT 13:00 EST 10:00 PST r/futurology.


The Major Mouse Testing Program is an ambitious project of the International Longevity Alliance, seeking to speed up scientific progress in the field of regenerative medicine and bio-gerontology. After ILA experts conducted an analysis of bottlenecks preventing the development of life extension technologies, it was revealed that one of these bottlenecks is the deficiency of robust animal data for the potential of different compounds to promote health and extend maximum lifespan. Without this data promising interventions cannot enter clinical trials and become available to the general public.

The ILA decided to initiate a fundraising program to fund a series of these high-risk studies: Major Mouse Testing Program. We are currently running a crowdfunding campaign for the first experiment to test a combination of Senolytics. They have been shown to help seek out and destroy senescent “death resistant” cells and improve various aspects of health. We wish to see if Senolytics are able increase maximum lifespan in addition to healthspan promotion. We have big plans for the future with combination testing of senolytics, stem cells and more to help speed up scientific progress. So go ahead ASK US ANYTHING!

Read more

Very promising. I hope within the next 10 years that Glioblastoma is eradicated.


A team from the International School for Advanced Studies (SISSA) in Trieste has obtained very promising results by applying gene therapy to glioblastoma. Tests in vitro and in vivo on mice provided very clear-cut results, and modelling demonstrates that the treatment targets at least six different points of tumour metabolism. Gene therapy, a technique that selectively attacks a tumour, might provide hope in the fight against this type of deadly cancer, for which surgery is practically impossible and chemo- and radiotherapy are ineffective against very aggressive recurrences. The study was published in the journal Oncotarget.

Only a few days ago, the press (especially in English-speaking countries) enthusiastically announced the publication of a study that described in great detail the genetics of breast cancer, a discovery that according to many marks a breakthrough in the battle against this cancer. This kind of news confirms the impression that in the near future the war against cancer will be fought on the battlefields of genetics. Italy too, is working on this front. At SISSA, for example, where Antonello Mallamaci and his group have just published highly promising results on the application of gene therapy against glioblastomas, a family of brain tumours among the most common and aggressive. A diagnosis of glioblastoma is literally equal to a very imminent death sentence: “surgery is rarely curative, as these tumours insinuate themselves in healthy tissues, and also chemo- and radiotherapy have little effectiveness.

Read more

Nice and interesting Gene Mutation Discovery.


A single defect in a gene that codes for a histone — a “spool” that wraps idle DNA — is linked to pediatric cancers in a study published in the journal Science.

“Unlike most cancers that require multiple hits, we found that this particular mutation can form a tumor all by itself,” says Peter W. Lewis, an assistant professor of biomolecular chemistry in the School of Medicine and Public Health at the University of Wisconsin-Madison.

Histones derive their pattern from the same genome that they help to pack up and organize. “A histone’s day job is compacting the genome,” says Lewis. “The histone takes six feet of DNA and packs it in something that is a few microns in diameter.”

Read more

I remember years ago when researchers identified that families with high rates for severe allergies also had high rates of cancer. Today, we talk about cancer and immunology as an intertwined dependency. Just means we’re still understanding cancer, genetic mutations, and the trigger/s in causing cancer among families and individual.


Scientists say the NLCR5 gene allows cancer cells to escape the immune system. A test for the biomarker may predict how long a cancer patient can survive.

Read more

Crowdfunding Campaign: https://www.lifespan.io/campaigns/the-major-mouse-testing-program/

We are testing a combination of compounds which clear out dysfunctional cells in the body, called Senolytics, to see if we can extend maximum lifespan and healthspan in mice. Please subscribe, share, and fund our Lifespan.io campaign today!

MMTP — Major Mouse Testing Program.
http://majormouse.org

Is a project by the International Longevity Alliance.

The community has the power to direct science and we no longer have to accept the traditional path of state funded science. We have the power to choose the direction science takes!


The cadence of SENS rejuvenation research fundraising this year will be a little different from that of past years. There will be more groups involved and more smaller initiatives running through existing crowdfunding sites for a start. The first of these fundraisers for 2016 has launched at crowdfunding site Lifespan.io, and is definitely worthy of our support. The Major Mouse Testing Program is a new non-profit group of researchers and advocates, who have spent the last six months making connections and laying the groundwork to run more animal studies of SENS-relevant prototype therapies focused on health and life span. This is an important gap in the longevity science community as it exists today: consider the painfully slow progress in organizing animal studies in senescent cell clearance over the past five years, for example. Given more enthusiasm and more funding, that could have happened a lot faster. Consider also that the research mainstream — such as the NIA Interventions Testing Program — carries out very few rigorous health and life span studies of potential interventions for aging in mice, and of those almost none are relevant to the SENS approach of damage repair, the only plausible path to radical life extension within our lifetimes.

Animal studies are vital; not just one or two, here or there, but a systematic approach to generating rigorous supporting data, establishing dosage, and uncovering unexpected outcomes. The Major Mouse Testing Program can do a great deal to fill this gap for our community, and has the potential to be an important supporting organization for the SENS Research Foundation, for startups working on SENS technologies such as Oisin Biotechnologies, and for labs involved in SENS research. The more diversity the better. The only thing that the Major Mouse Testing Program lacks today is the initial funding and support that we can provide to give them a good start on their plans for the future. With clever organization, a non-profit organization allied with established labs can carry out solid animal studies at a cost low enough for people like you and I to fund the work via fundraisers, and that is exactly what we should do.

I have stepped up to donate to this first fundraiser for the Major Mouse Testing Program, and I hope that you will too. This is a useful, needed initiative, the people involved are solid members of the community, doing the right thing, and pulling together the right networks, and they deserve our support. This first crowdfunding initiative is focused on expanding animal studies of drug-based senescent cell clearance approaches, in collaboration with existing groups that are working in this field. Remember, however, that this isn’t just about setting up one set of experiments. This is the first step in building out an organization that can help greatly in the years to come, as the field of potential rejuvenation treatments expands, and the need grows for the non-profit groups in our community to specialize and diversify.


University of Oxford scientists have developed a gene therapy that has shown promise in treating choroideremia, a rare disorder that causes progressive vision loss, mostly in males.

Doctors tested the treatment method on six patients with choroideremia by injecting numerous healthy genes into the eye to replace missing ones in the retina. The purpose of this therapy is to hinder or prevent loss of sight, according to Oxford’s announcement.

Results varied for each participant. Two patients experienced a big improvement in vision that lasted for four years, but a decline occurred in the other untreated eye. Three separate patients maintained their vision in the treated eye over four years whereas the sixth recipient who was given a lower dose succumbed to vision decline in both eyes.

Read more